Novo A/S
Latest statistics and disclosures from Novo Holdings A/S's latest quarterly 13F-HR filing:
- Top 5 stock holdings are VTI, BN, ASML, MIRM, EWTX, and represent 52.93% of Novo Holdings A/S's stock portfolio.
- Added to shares of these 7 stocks: Bridgebio Oncology Therapeut (+$23M), ELVN (+$7.0M), Lanzatech Global, CRNX, APGE, AVBP, PHVS.
- Started 2 new stock positions in Bridgebio Oncology Therapeut, Lanzatech Global.
- Reduced shares in these 10 stocks: INSM (-$69M), BPMC (-$34M), BABA (-$21M), ASML (-$19M), MIRM (-$17M), CBLL (-$17M), RXRX (-$8.5M), ZBIO (-$5.6M), LNZA, ABCL.
- Sold out of its positions in ABCL, BPMC, CBLL, LNZA.
- Novo Holdings A/S was a net seller of stock by $-158M.
- Novo Holdings A/S has $1.6B in assets under management (AUM), dropping by 9.53%.
- Central Index Key (CIK): 0001388325
Tip: Access up to 7 years of quarterly data
Positions held by Novo A/S consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Novo Holdings A/S
Novo Holdings A/S holds 27 positions in its portfolio as reported in the September 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Vanguard Index Fds Total Stk Mkt (VTI) | 22.0 | $341M | 1.0M | 328.17 |
|
|
| Brookfield Corp Cl A Ltd Vt Sh (BN) | 10.3 | $160M | 2.3M | 68.58 |
|
|
| Asml Holding N V N Y Registry Shs (ASML) | 9.1 | $141M | -12% | 146k | 968.09 |
|
| Mirum Pharmaceuticals (MIRM) | 6.0 | $93M | -15% | 1.3M | 73.31 |
|
| Edgewise Therapeutics (EWTX) | 5.6 | $87M | 5.4M | 16.22 |
|
|
| salesforce (CRM) | 5.0 | $78M | 330k | 237.00 |
|
|
| Merus N V (MRUS) | 4.6 | $71M | 750k | 94.15 |
|
|
| Crinetics Pharmaceuticals In (CRNX) | 4.4 | $68M | +4% | 1.6M | 41.65 |
|
| Miragen Therapeutics (VRDN) | 3.3 | $51M | 2.4M | 21.58 |
|
|
| Alibaba Group Hldg Sponsored Ads (BABA) | 3.0 | $46M | -30% | 257k | 178.73 |
|
| Zenas Biopharma (ZBIO) | 2.9 | $44M | -11% | 2.0M | 22.20 |
|
| Pharvaris N V (PHVS) | 2.8 | $44M | 1.8M | 24.95 |
|
|
| Recursion Pharmaceuticals In Cl A (RXRX) | 2.5 | $39M | -17% | 7.9M | 4.88 |
|
| Arrivent Biopharma (AVBP) | 2.3 | $36M | +3% | 1.9M | 18.45 |
|
| BioMarin Pharmaceutical (BMRN) | 2.3 | $36M | 660k | 54.16 |
|
|
| Vaxcyte (PCVX) | 2.1 | $33M | 916k | 36.02 |
|
|
| Celldex Therapeutics Com New (CLDX) | 2.0 | $31M | 1.2M | 25.87 |
|
|
| Enliven Therapeutics (ELVN) | 1.9 | $29M | +31% | 1.4M | 20.47 |
|
| Insmed Com Par $.01 (INSM) | 1.9 | $29M | -70% | 200k | 144.01 |
|
| Valneva Se Sponsored Ads (VALN) | 1.8 | $29M | 2.3M | 12.20 |
|
|
| Bridgebio Oncology Therapeut Com New | 1.5 | $23M | NEW | 2.0M | 11.58 |
|
| Apogee Therapeutics (APGE) | 1.3 | $20M | +11% | 500k | 39.73 |
|
| 4d Molecular Therapeutics In (FDMT) | 1.1 | $17M | 2.0M | 8.69 |
|
|
| Lanzatech Global Com New | 0.2 | $3.9M | NEW | 158k | 24.51 |
|
| Marqeta Class A Com (MQ) | 0.2 | $2.3M | 442k | 5.28 |
|
|
| Io Biotech (IOBT) | 0.1 | $912k | -25% | 2.5M | 0.36 |
|
| Galecto Com New (GLTO) | 0.0 | $322k | -13% | 87k | 3.72 |
|
Past Filings by Novo Holdings A/S
SEC 13F filings are viewable for Novo Holdings A/S going back to 2014
- Novo Holdings A/S 2025 Q3 filed Nov. 14, 2025
- Novo Holdings A/S 2025 Q2 filed Aug. 14, 2025
- Novo Holdings A/S 2025 Q1 filed May 15, 2025
- Novo Holdings A/S 2024 Q4 filed Feb. 14, 2025
- Novo Holdings A/S 2024 Q3 filed Oct. 24, 2024
- Novo Holdings A/S 2024 Q2 restated filed Aug. 20, 2024
- Novo Holdings A/S 2024 Q1 filed May 15, 2024
- Novo Holdings A/S 2023 Q4 filed Feb. 14, 2024
- Novo Holdings A/S 2023 Q3 filed Nov. 14, 2023
- Novo Holdings A/S 2023 Q2 filed Aug. 14, 2023
- Novo Holdings A/S 2023 Q1 filed May 15, 2023
- Novo Holdings A/S 2022 Q4 filed Feb. 14, 2023
- Novo Holdings A/S 2022 Q3 filed Nov. 14, 2022
- Novo Holdings A/S 2022 Q2 filed Aug. 15, 2022
- Novo Holdings A/S 2022 Q1 restated filed May 27, 2022
- Novo Holdings A/S 2022 Q1 filed May 16, 2022